Richard C Austin Selected Research

Endoplasmic Reticulum Chaperone BiP

5/2022	Scratching the Surface-An Overview of the Roles of Cell Surface GRP78 in Cancer.
1/2021	Glucose-regulated protein (GRP78) is an important cell surface receptor for viral invasion, cancers, and neurological disorders.
10/2019	Cell surface expression of 78-kDa glucose-regulated protein (GRP78) mediates diabetic nephropathy.
1/2019	GRP78 (Glucose-Regulated Protein of 78 kDa) Promotes Cardiomyocyte Growth Through Activation of GATA4 (GATA-Binding Protein 4).
12/2018	Anti-GRP78 autoantibodies induce endothelial cell activation and accelerate the development of atherosclerotic lesions.
1/2018	Endoplasmic Reticulum Chaperone GRP78 Protects Heart From Ischemia/Reperfusion Injury Through Akt Activation.
12/2017	Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor.
1/2016	GRP78 and CHOP modulate macrophage apoptosis and the development of bleomycin-induced pulmonary fibrosis.
3/2011	Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: endoplasmic reticulum stress as a mediator of pathogenesis.
9/2010	Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard C Austin Research Topics

Disease

17	Atherosclerosis 11/2021 - 06/2003
12	Neoplasms (Cancer) 05/2022 - 07/2002
7	Hyperhomocysteinemia 06/2013 - 06/2003
6	Cardiovascular Diseases (Cardiovascular Disease) 02/2022 - 08/2003
5	Inflammation (Inflammations) 11/2021 - 11/2003
3	Atherosclerotic Plaque (Atheroma) 11/2021 - 06/2003
3	Cardiomegaly (Heart Hypertrophy) 01/2019 - 03/2011
3	Prostatic Neoplasms (Prostate Cancer) 12/2017 - 09/2010
3	Thrombosis (Thrombus) 06/2010 - 01/2007
2	Fibrosis (Cirrhosis) 01/2018 - 01/2016
2	Adenocarcinoma 05/2017 - 05/2009
2	Renal Cell Carcinoma (Grawitz Tumor) 02/2014 - 01/2014
2	Necrosis 05/2013 - 09/2012
2	Weight Gain 01/2013 - 12/2009
2	Vascular Diseases (Vascular Disease) 09/2008 - 08/2004
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 02/2022
1	Type 2 Diabetes Mellitus (MODY) 11/2021
1	Coronary Artery Disease (Coronary Atherosclerosis) 10/2021
1	Teratocarcinoma 01/2021
1	Nervous System Diseases (Neurological Disorders) 01/2021
1	Chronic Renal Insufficiency 01/2020
1	Hyperphosphatemia 01/2020
1	Alcoholic Fatty Liver 12/2019
1	Non-alcoholic Fatty Liver Disease 12/2019
1	Carcinogenesis 10/2019
1	Diabetic Nephropathies (Diabetic Nephropathy) 10/2019
1	Liver Diseases (Liver Disease) 01/2019
1	Fatty Liver 01/2019
1	Acquired Immunodeficiency Syndrome (AIDS) 12/2018
1	Coronary Disease (Coronary Heart Disease) 01/2018
1	Reperfusion Injury 01/2018
1	Dyslipidemias (Dyslipidemia) 01/2018
1	Melanoma (Melanoma, Malignant) 01/2018
1	Experimental Melanoma 01/2018
1	Carcinoma (Carcinomatosis) 05/2017

Drug/Important Bio-Agent (IBA)

16	Proteins (Proteins, Gene)FDA Link 02/2022 - 07/2002
13	Endoplasmic Reticulum Chaperone BiPIBA 05/2022 - 05/2003
11	Apolipoproteins E (ApoE)IBA 11/2021 - 06/2003
9	LipidsIBA 11/2021 - 06/2003
7	ApolipoproteinsIBA 01/2018 - 06/2003
6	CholesterolIBA 02/2022 - 05/2013
6	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 05/2013
6	HomocysteineIBA 03/2009 - 06/2003
5	AutoantibodiesIBA 05/2022 - 09/2010
4	LDL Receptors (LDL Receptor)IBA 02/2022 - 11/2016
3	LDL CholesterolIBA 01/2021 - 06/2013
3	Thromboplastin (Tissue Factor)IBA 12/2017 - 06/2010
3	Methionine (L-Methionine)FDA Link 09/2008 - 06/2003
2	SubtilisinIBA 02/2022 - 11/2018
2	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA 02/2022 - 11/2018
2	AMP-Activated Protein KinasesIBA 11/2021 - 02/2014
2	ProdrugsIBA 11/2021 - 11/2016
2	HDL CholesterolIBA 10/2021 - 01/2018
2	Proprotein Convertase 9IBA 01/2021 - 01/2019
2	4-phenylbutylamineIBA 01/2019 - 12/2009
2	Molecular Chaperones (Chaperone, Molecular)IBA 12/2018 - 12/2017
2	Thrombin FDA Link 01/2018 - 05/2003
2	Prostate-Specific Antigen (Semenogelase)IBA 12/2017 - 05/2017
2	EpitopesIBA 12/2017 - 09/2010
2	Small Interfering RNA (siRNA)IBA 05/2017 - 02/2014
2	AdiponectinIBA 02/2014 - 01/2014
2	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 06/2013 - 01/2011
2	CytokinesIBA 05/2013 - 07/2002
2	Vitamin B Complex (B Vitamins)IBA 03/2009 - 06/2003
1	Caffeine (No Doz)FDA LinkGeneric 01/2022
1	salicylsalicylic acid (salsalate)IBA 11/2021
1	Acetyl-CoA CarboxylaseIBA 11/2021
1	Blood Glucose (Blood Sugar)IBA 11/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 11/2021
1	Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)IBA 11/2021
1	SalicylatesIBA 11/2021
1	Cell Surface ReceptorsIBA 01/2021
1	AutoantigensIBA 01/2021
1	Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA 01/2021
1	LigandsIBA 01/2021
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021
1	Cholecalciferol (Vitamin D3)FDA Link 01/2020
1	Phosphates (Orthophosphate)IBA 01/2020
1	Triglycerides (Triacylglycerol)IBA 12/2019
1	Glycoside Hydrolases (Endoglycosidases)IBA 01/2018
1	Interleukin-6 (Interleukin 6)IBA 01/2018
1	Oncostatin MIBA 01/2018
1	Scavenger Receptors (Scavenger Receptor)IBA 01/2018
1	Lipoproteins (Lipoprotein)IBA 01/2018
1	VLDL LipoproteinsIBA 01/2018
1	Plasminogen Activator Inhibitor 1IBA 01/2018
1	Neuraminidase (Sialidase)IBA 01/2018
1	Rosuvastatin Calcium (Crestor)FDA Link 01/2018
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2018
1	PF-429242IBA 01/2018
1	Heparin (Liquaemin)FDA LinkGeneric 12/2017
1	Pharmaceutical PreparationsIBA 12/2017
1	Complementary DNA (cDNA)IBA 05/2017
1	ElementsIBA 01/2017
1	Transcription Factors (Transcription Factor)IBA 01/2017
1	SterolsIBA 01/2017
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2017
1	oxidized low density lipoproteinIBA 11/2016

Therapy/Procedure

2	Therapeutics 05/2022 - 11/2016
1	Secondary Prevention 01/2018